Synlogic announces synthetic biotic for gout developed in partnership with ginkgo bioworks

Synb2081 is the second clinical drug candidate developed through the partnership between ginkgo and synlogic cambridge, mass. and boston , aug. 11, 2022 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced a new drug candidate for the treatment of gout developed in partnership with ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming.
SYBX Ratings Summary
SYBX Quant Ranking